logo-loader

Oventus Medical advancing unique sleep apnoea appliance

Published: 13:30 01 May 2017 AEST

Sleep
Oventus technology to be deployed as a new treatment option for sleep apnoea

Oventus Medical (ASX:OVN) is making significant clinical progress with its O2Vent oral appliance for the treatment of sleep apnoea and snoring.

The system is designed to bridge the gap between current oral appliances, delivered by dentists, and PAP therapy, which is typically delivered by sleep clinicians or specialist sleep centres.

PAP or positive airway pressure therapy uses a machine to help a person who has obstructive sleep apnea (OSA) breathe more easily during sleep.

Oventus’ hybrid system is designed to address two key issues: the clinical effectiveness of oral appliances for sleep apnoea and the non-compliance of PAP patients to therapy.

The results of the initial pilot study announced earlier this year showed the benefit of the O2Vent airway in reducing pressure swings and collapsibility – the cause of obstructive sleep apnoea.

The abstract for this initial pilot study has now been accepted for Sleep 2017, the premier world forum for the presentation and discussion of latest developments in clinical sleep medicine.

Sleep 2017 is to be held in Boston in the first week of June 2017.

Following the completion of the pilot study, the PAP connector system has completed the optimisation of the design process and is being used in the expanded PAP connection study.

The trial is now underway following the recruitment of the first patient.

Oventus is well funded with a cash balance of circa $5 million as at 31 March 2017.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

13 hours, 4 minutes ago